This page is part of the Genetic Reporting Implementation Guide (v3.0.0: STU3) based on FHIR (HL7® FHIR® Standard) R4. This is the current published version. For a full list of available versions, see the Directory of published versions
Generated Narrative: Procedure genomicstudy-trio2
Genomic Study Referrer Extension: Practitioner Jane Doel
identifier: http://www.somesystemabc.net/identifiers/genomicstudies
/urn:uuid:1111-1111-1111-1113 (use: temp, )
status: Completed
category: Laboratory
code: Trio Analysis
performed: 2023-10-01
asserter: Practitioner Jane Doel
note: De novo mutation study of the patient. The Prenatal Trio Whole Exome Sequencing (Prenatal Trio WES) test is ordered by a physician and must be accompanied with a consent form and detailed clinical information. In general, the test is used when prenatal imaging detects an anomaly that strongly suggests that there is an underlying genetic etiology. Prenatal Trio WES is often considered only after fetal chromosome microarray analysis has been non-diagnostic.